Switching to Generic Eye Meds Could Save Medicare Millions

This article originally appeared here.
Share this content:
Switching to Generic Eye Meds Could Save Medicare Millions
Switching to Generic Eye Meds Could Save Medicare Millions

FRIDAY, July 28, 2017 (HealthDay News) -- Prescribing generic drugs for seniors' eye problems could save the U.S. government hundreds of millions of dollars a year, according to a study published recently in Ophthalmology.

Eye care specialists prescribe more brand-name drugs by volume than any other group of health care providers, according to the researchers. In 2013, eye care providers generated $2.4 billion in annual Medicare Part D prescription costs. The study authors analyzed those costs, and showed that switching to lower-cost generics could save $882 million a year. Also, negotiating prices with drug makers could save $1.09 billion a year.

Looking at specific eye conditions, the investigators found that glaucoma medications made up half of prescription eye drugs -- at a cost of $1.2 billion. Dry eye medications claimed the second highest billing, mostly due to one drug, cyclosporine (Restasis), which has no generic equivalent. Restasis was the most-used eye medication among Medicare Part D beneficiaries, accounting for $371 million in spending.

"Lawmakers are currently looking for ways to reduce federal spending for health care, and policies that favor generics over brand medications or allow Medicare to negotiate drug prices may lead to cost savings," senior author Lindsey De Lott, M.D., of the University of Michigan Kellogg Eye Center in Ann Arbor, said in a university news release. "Using a brand medication for a single patient may not seem like a big deal, but ultimately, these higher costs are paid by all of us."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

FDA Approves New Treatment for Acute Lymphoblastic Leukemia

For patients with relapsed or refractory B-cell ALL who have received one or two prior treatments

Online Nursing Education Can Up Patient Use of VTE Prophylaxis

Online Nursing Education Can Up Patient Use of ...

Online training aims to make sure those hospitalized get treatment to prevent venous thromboembolism

On-Pump CABG Leads to Higher Rates of Five-Year Survival

On-Pump CABG Leads to Higher Rates of Five-Year ...

Study compared coronary-artery bypass grafting surgery, with/without cardiopulmonary bypass

is free, fast, and customized just for you!

Already a member?

Sign In Now »